Surgical Hemostats Market, By Product Type (Topical Thrombin-Based, Flowable, Collagen-Based, Oxidized Regenerated Cellulose-Based, Gelatin-Based, & Combination), Formulation (Matrix, Sponge, Powder), Application, End-use -Global Forecast (2024-2032)

Surgical Hemostats Market, By Product Type (Topical Thrombin-Based, Flowable, Collagen-Based, Oxidized Regenerated Cellulose-Based, Gelatin-Based, & Combination), Formulation (Matrix, Sponge, Powder), Application, End-use -Global Forecast (2024-2032)

Surgical Hemostats Market size is poised to expand at 5.6% CAGR from 2024 to 2032 driven by the concerted efforts to minimize postoperative complications.

Of late, surgeons are prioritizing effective hemostatic solutions to control bleeding during and after surgical procedures for reducing the risk of complications and improving patient outcomes. Healthcare professionals are increasingly emphasizing patient safety and recovery, surging the adoption of advanced hemostatic agents. The continuous development of innovative hemostatic technologies, aimed at enhancing efficacy and minimizing adverse effects will fuel the product adoption. Furthermore, the ongoing innovations in hemostatic agents, including the development of advanced materials and formulations to improve efficacy and applicability will contribute to the industry growth. For instance, in November 2023, Ethicon announced the approval of ETHIZIATM, a clinically certified supplementary hemostat solution to maintain hemostasis in circumstances of difficult-to-control bleeding.

The industry is segmented into product type, formulation, application, end-use, and region.

Based on product type, the collagen-based surgical hemostats market is projected to witness 5.2% CAGR between 2024 and 2032. This is owing to the increasing preference for collagen-based products for their versatility and ability to control bleeding effectively. Surgical hemostats provide hemostatic efficacy, biocompatibility, and ease of use in various surgical applications. Additionally, the natural hemostatic properties of collagen are surging its use for diverse surgeries, including orthopedic, cardiovascular, and dental procedures. Furthermore, technological advancements to enhance the performance and applicability of collagen-based hemostats will propel the segment growth.

In terms of end-use, the surgical hemostats industry from the ambulatory surgical centers segment is expected to record 5.4% growth rate through 2032. The growing patient preference for medical treatments at ambulatory surgical centers (ASCs) can be attributed to their efficiency, cost-effectiveness, and minimally invasive procedures. The rising need for effective bleeding control in diverse surgical interventions performed in outpatient settings is also fueling the product demand.

Asia Pacific surgical hemostats industry is set to exhibit 6% growth rate during 2024-2032 attributed to the rising surgical procedures, increasing healthcare infrastructure, and the growing awareness about advanced medical products. The surging prevalence of chronic diseases and elective surgeries is contributing to the higher demand for efficient hemostatic solutions. Moreover, government initiatives for promoting healthcare development coupled with the ongoing advancements in surgical techniques and the strong focus on minimizing postoperative complications will accelerate the regional industry expansion.